Pulmonx Corp
NASDAQ:LUNG
Intrinsic Value
Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. [ Read More ]
The intrinsic value of one LUNG stock under the Base Case scenario is 10.84 USD. Compared to the current market price of 7.3 USD, Pulmonx Corp is Undervalued by 33%.
Valuation Backtest
Pulmonx Corp
Run backtest to discover the historical profit from buying and selling LUNG stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Pulmonx Corp
Current Assets | 150.4m |
Cash & Short-Term Investments | 58.7m |
Receivables | 13m |
Other Current Assets | 78.7m |
Non-Current Assets | 27.4m |
Long-Term Investments | 14.4m |
PP&E | 7.4m |
Intangibles | 2.4m |
Other Non-Current Assets | 3.2m |
Current Liabilities | 23.2m |
Accounts Payable | 1.5m |
Accrued Liabilities | 18.8m |
Other Current Liabilities | 2.8m |
Non-Current Liabilities | 36.3m |
Long-Term Debt | 35.1m |
Other Non-Current Liabilities | 1.2m |
Earnings Waterfall
Pulmonx Corp
Revenue
|
68.7m
USD
|
Cost of Revenue
|
-17.9m
USD
|
Gross Profit
|
50.8m
USD
|
Operating Expenses
|
-112.7m
USD
|
Operating Income
|
-61.9m
USD
|
Other Expenses
|
1.1m
USD
|
Net Income
|
-60.8m
USD
|
Free Cash Flow Analysis
Pulmonx Corp
LUNG Profitability Score
Profitability Due Diligence
Pulmonx Corp's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Pulmonx Corp's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
LUNG Solvency Score
Solvency Due Diligence
Pulmonx Corp's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Pulmonx Corp's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LUNG Price Targets Summary
Pulmonx Corp
According to Wall Street analysts, the average 1-year price target for LUNG is 16.52 USD with a low forecast of 14.14 USD and a high forecast of 17.85 USD.
Ownership
LUNG Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LUNG Price
Pulmonx Corp
Average Annual Return | -22.54% |
Standard Deviation of Annual Returns | 67.17% |
Max Drawdown | -93% |
Market Capitalization | 281.2m USD |
Shares Outstanding | 38 811 800 |
Percentage of Shares Shorted | 4.14% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
Contact
IPO
Employees
Officers
The intrinsic value of one LUNG stock under the Base Case scenario is 10.84 USD.
Compared to the current market price of 7.3 USD, Pulmonx Corp is Undervalued by 33%.